Ernexa Therapeutics (ERNAW) Current Leases (2010 - 2026)

Ernexa Therapeutics (ERNAW) has 17 years of Current Leases data on file, last reported at $163000.0 in Q1 2026.

• Quarterly Current Leases fell 23.47% year-over-year to $163000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $163000.0 (down 23.47% YoY) and the FY2025 annual result came in at $213000.0, up 2.9% from the prior year.
• Current Leases eased to $163000.0 in Q1 2026, from $213000.0 in the prior quarter.
• In the past five years, Current Leases ranged from a high of $4.3 million in Q2 2024 to a low of $149000.0 in Q1 2022.
• A 5-year average of $796235.3 and a median of $213000.0 in 2025 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2024 — Current Leases soared 2365.9% — and 2025, when it slumped 94.91%.
• Tracing ERNAW's Current Leases over 5 years: stood at $295000.0 in 2022, then jumped by 651.19% to $2.2 million in 2023, then sank by 90.66% to $207000.0 in 2024, then gained by 2.9% to $213000.0 in 2025, then fell by 23.47% to $163000.0 in 2026.
• The last three Current Leases figures came in at $163000.0 (Q1 2026), $213000.0 (Q4 2025), and $206000.0 (Q3 2025), per Business Quant data.